Grey matter network markers identify individuals with prodromal Alzheimer's disease who will show rapid clinical decline.

ABSTRACT: Individuals with prodromal Alzheimer's disease show considerable variability in rates of cognitive decline, which hampers the ability to detect potential treatment effects in clinical trials. Prognostic markers to select those individuals who will decline rapidly within a trial time frame are needed. Brain network measures based on grey matter covariance patterns have been associated with future cognitive decline in Alzheimer's disease. In this longitudinal cohort study, we investigated whether cut-offs for grey matter networks could be derived to detect fast disease progression at an individual level. We further tested whether detection was improved by adding other biomarkers known to be associated with future cognitive decline [i.e. CSF tau phosphorylated at threonine 181 (p-tau181) leve

SUBMITTER: Pelkmans W 

PROVIDER: S-EPMC8924646 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature